Evidence map›Paper›PMID 39852661›Full record

ArticleTropical medicine and infectious disease2024

Assessing the Acceptability and Feasibility of Five Cycles of Seasonal Malaria Chemoprevention in Côte d'Ivoire.

Orphée Kangah, Issaka Zongo, Alassane Haro, William Yavo

Abstract read
In one paragraph

Article in Tropical medicine and infectious disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genetic Diversity ofTropical medicine and infectious disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Orphée KangahNational Institute of Public Health, Abidjan BP V 47, Côte d'Ivoire.
Issaka ZongoInstitut de Recherche en Sciences de la Santé-Direction Régionale de l'Ouest (IRSS-DRO), Bobo-Dioulasso BP 2779, Burkina Faso.
Alassane HaroInstitut de Recherche en Sciences de la Santé-Direction Régionale de l'Ouest (IRSS-DRO), Bobo-Dioulasso BP 2779, Burkina Faso.
William YavoNational Institute of Public Health, Abidjan BP V 47, Côte d'Ivoire.

Funding

European and Developing Countries Clinical Trials Partnership (EDCTP) TMA2019SFP-2834
6 · The paper itself

Abstract

Seasonal malaria chemoprevention (SMC) is a strategy recommended by the World Health Organization for children aged 3-59 months in the Sahel and sub-Sahel regions where malaria transmission is seasonal. In Côte d'Ivoire, malaria remains a high priority and accounts for the majority of consultations and deaths in children under five. The recent revision of the criteria for the introduction of seasonal malaria chemoprevention has made the north of Côte d'Ivoire, where malaria transmission is seasonal, eligible for the SMC. We conducted a pilot study in this part of the country to assess the acceptability and feasibility of five cycles of SMC in 1701 children. Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine + amodiaquine (SP + AQ) was administered monthly to eligible children over five months. A qualitative approach and quantitative surveys were used to assess the strategy acceptability and feasibility in the study area. Overall, there was a positive perception, attitude, and adherence towards the seasonal malaria chemoprevention in this study area.

Indexed as

acceptabilityfeasibilitynorth Côte d’Ivoireseasonal malaria chemoprevention

Identifiers

PMID39852661
PMCPMC11768516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.